Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREND-HD: Ethyl-EPA in Huntington's Disease
NCT00146211Phase 3Completed
- Sponsor
- Amarin Corporation plc
- Start
- Sep 2005
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Huntington disease (HD) comparing Ethyl-EPA with Placebo (2 arms). Primary endpoint: Total Motor Score-4 component of the Unified Huntington's Disease Rating Scale at 6 months. Started Sep 2005; status: completed.
02
Drugs
Epadel
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT00146211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146211.